- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,031GBP
- Report
- November 2023
- 630 Pages
Global
From €9128EUR$9,500USD£7,836GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- August 2018
- 16 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- August 2018
- 22 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- August 2018
- 16 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- April 2021
- 191 Pages
Global
€21139EUR$22,000USD£18,146GBP
- Report
- April 2019
- 93 Pages
Global
From €3123EUR$3,250USD£2,681GBP
- Report
- August 2018
- 19 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,186GBP
Crizotinib is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of tyrosine kinase inhibitor (TKI) that works by blocking the activity of a protein called anaplastic lymphoma kinase (ALK). This protein is found in some types of NSCLC and is responsible for the growth and spread of cancer cells. Crizotinib is used to treat advanced NSCLC that has spread to other parts of the body and is caused by a mutation in the ALK gene. It is also used to treat a type of NSCLC called ROS1-positive NSCLC.
Crizotinib is available in tablet form and is taken orally. It is usually taken twice a day, with or without food. Common side effects of crizotinib include nausea, vomiting, diarrhea, fatigue, and liver problems.
Crizotinib is a relatively new drug and is one of several targeted therapies used to treat NSCLC. It is an important treatment option for patients with ALK-positive or ROS1-positive NSCLC.
Companies in the Crizotinib market include Pfizer, Merck, AstraZeneca, and Novartis. Show Less Read more